What is William Blair’s Estimate for ELEV Q2 Earnings?

Elevation Oncology, Inc. (NASDAQ:ELEV) – Stock analysts at William Blair issued their Q2 2025 EPS estimates for shares of Elevation Oncology in a research note issued to investors on Friday, March 7th. William Blair analyst A. Hsieh forecasts that the company will post earnings per share of ($0.21) for the quarter. William Blair currently has a “Outperform” rating and a $5.00 target price on the stock. The consensus estimate for Elevation Oncology’s current full-year earnings is ($0.84) per share. William Blair also issued estimates for Elevation Oncology’s Q3 2025 earnings at ($0.21) EPS and Q4 2025 earnings at ($0.24) EPS.

Several other equities analysts have also recently weighed in on the stock. Stephens reiterated an “overweight” rating and issued a $5.00 price objective on shares of Elevation Oncology in a research note on Friday. JMP Securities reiterated a “market outperform” rating and issued a $7.00 price objective on shares of Elevation Oncology in a research note on Thursday, December 19th. Finally, HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of Elevation Oncology in a research note on Monday. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $6.83.

Elevation Oncology Price Performance

Shares of NASDAQ:ELEV opened at $0.47 on Monday. The firm’s 50 day moving average price is $0.64 and its 200-day moving average price is $0.62. Elevation Oncology has a twelve month low of $0.41 and a twelve month high of $5.83. The company has a quick ratio of 17.77, a current ratio of 17.77 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $27.82 million, a PE ratio of -0.57 and a beta of 1.37.

Elevation Oncology (NASDAQ:ELEV) last issued its quarterly earnings data on Thursday, March 6th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.04.

Institutional Investors Weigh In On Elevation Oncology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ELEV. GSA Capital Partners LLP bought a new stake in Elevation Oncology during the 3rd quarter worth approximately $260,000. State Street Corp raised its stake in Elevation Oncology by 13.5% during the 3rd quarter. State Street Corp now owns 1,018,026 shares of the company’s stock worth $611,000 after acquiring an additional 120,993 shares during the period. Sphera Funds Management LTD. raised its stake in Elevation Oncology by 227.2% during the 3rd quarter. Sphera Funds Management LTD. now owns 1,079,762 shares of the company’s stock worth $648,000 after acquiring an additional 749,762 shares during the period. Barclays PLC raised its stake in Elevation Oncology by 302.4% during the 3rd quarter. Barclays PLC now owns 72,077 shares of the company’s stock worth $43,000 after acquiring an additional 54,167 shares during the period. Finally, Frazier Life Sciences Management L.P. raised its stake in Elevation Oncology by 102.6% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 5,993,579 shares of the company’s stock worth $3,596,000 after acquiring an additional 3,035,000 shares during the period. Institutional investors own 83.70% of the company’s stock.

About Elevation Oncology

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.